3 Stocks That Could Be Held For The Next 20 Years - Moderna

3 – Moderna

Founded in 2010 as the first biotechnology center focused on mRNA technology, Moderna has been working and making improvements on the messenger RNA (mRNA) project for decades. The impact of COVID-19 on the world has been a coincidence for companies as well as everyone. COVID-19 vaccines provided by Moderna and BioNtech (NASDAQ: BNTX) were among the first to use nRNA technology. The success with COVID may have ushered in a new world where mRNA technology can be used to combat not only viruses but also autoimmune diseases, cancer and cardiovascular diseases.

Over the past year Moderna's fortune has changed dramatically, turning from an early-stage biotech company into a highly profitable pharmaceutical giant.

Analysts expect Moderna to earn $ 9.3 billion, or $ 23.27 per share, this fiscal year, but that figure is expected to decline to $ 16.58 per share in 2022.

Moderna now has the ability to self-fund research and development projects instead of raising money, and there are also a number of mRNA applications under development.

The company is about to begin stage 3 trials on the cytomegalovirus vaccine, the number one cause of birth defects today. Additionally, Moderna's Phase 1 and Phase 2 trials include a variety of oncology and cardiovascular disease treatments. The company will also benefit from treatments to combat existing or future COVID variants. As of now, investors are pricing COVID-driven profits fairly well, but likely Moderna is expected to find even more significant treatments over the next decade.   3 Stocks That Could Be Held For The Next 20 Years - Moderna Source: https://www.fool.com/ You may also be interested in:

3 Stocks That Could Be Held For The Next 20 Years - Mastercard